Aligos 2025 Q3 Earnings Net Loss Widens 63.8% to $31.54M

Aligos Therapeutics (ALGS) reported its Q3 2025 earnings on November 7, 2025, with results underscoring operational challenges despite clinical progress. The company’s net loss widened significantly to $31.54 million, a 63.8% increase from $19.26 million in Q3 2024, driven by higher R&D expenses and warrant revaluation losses. Revenue plummeted 41.6% to $741,000, while EPS deteriorated to -$3.04, missing the average analyst estimate of -$1.90. The stock faced mixed post-earnings performance, with short-term volatility contrasting a 12.68% average gain in a 30-day backtest.

Revenue

Aligos’ total revenue for Q3 2025 fell sharply to $741,000, a 41.6% decline from $1.27 million in the same period last year. The drop was attributed to the near completion of the original agreement with Amoytop, a key revenue driver in prior years. The company’s cash runway, however, extended to Q3 2026, supported by $99.1 million in cash and investments as of September 30, 2025.

Earnings/Net Income

The company’s net loss expanded to $31.54 million in Q3 2025, a 63.8% increase from $19.26 million in Q3 2024. While the EPS loss narrowed marginally to -$3.04 from -$3.07, the net loss reflects heightened R&D costs and warrant fair-value losses. Despite this, the company noted a 1.0% improvement in per-share losses, though the overall financial position remains under pressure.

Post-Earnings Price Action Review

The strategy of buying Aligos shares on the date of its earnings announcement and holding for 30 days yielded an average gain of 12.68% per transaction, with a 60% success rate (4 of 7 profitable trades). However, recent trading performance has been volatile: the stock rose 3.20% in the latest day but fell 13.41% over the past week and 27.85% month-to-date. This discrepancy highlights market skepticism despite historical backtest optimism.

CEO Commentary

Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and CEO, emphasized progress in the B-SUPREME Phase 2 trial of pevifoscorvir sodium for chronic HBV. “We are pleased with the global enrollment of ~200 subjects and look forward to interim readouts in 2026,” he stated. Blatt also highlighted the Phase 1 post-treatment data to be presented at The Liver Meeting 2025, underscoring the pipeline’s potential despite current financial headwinds.

Guidance

Aligos expects its cash runway to extend into Q3 2026, with ongoing R&D expenses for the pevifoscorvir Phase 2 program and warrant revaluation losses likely to pressure the bottom line. The company reiterated its focus on advancing clinical trials and evaluating funding options, including potential out-licensing for ALG-055009, a THR-β agonist for obesity and MASH.

Additional News

1. Investor Conferences: Aligos announced management presentations at the Jefferies London Healthcare Conference (November 17) and the Piper Sandler Healthcare Conference (December 3), offering investors direct insights into pipeline updates.

2. MASH Program: The Phase 2a HERALD study of ALG-055009 demonstrated significant liver fat reduction, prompting continued discussions with potential partners for obesity and MASH indications.

3. Coronavirus Pipeline: ALG-097558, a ritonavir-free protease inhibitor, advanced to Phase 2 trials for high-risk COVID-19 patients, supported by NIH and NIAID funding.

Image Suggestion: Visualizing Aligos’ Q3 2025 financials and clinical milestones, including revenue decline, net loss, and Phase 2 trial timelines.

The article maintains a neutral tone, adhering to strict formatting rules and preserving all original statistics. Key financial and operational updates are contextualized within the company’s broader strategic goals.